Clinical TrialApr 27, 2026, 08:06 AM
IRTC: Zio 14-day monitoring detects more arrhythmias post-ablation & pregnancy
AI Summary
iRhythm Holdings, Inc. announced results from two real-world retrospective analyses presented at HRS 2026, demonstrating the superior detection capabilities of its Zio ambulatory ECG devices. The studies in post-ablation and pregnancy patient populations showed that Zio's continuous 14-day monitoring detected a significant proportion of arrhythmias (26% of AF recurrence post-ablation, 60% of arrhythmias in pregnancy) beyond 48 hours, which would be missed by short-duration Holter monitoring. These findings reinforce the clinical value of Zio devices for a more complete assessment of arrhythmia burden.
Key Highlights
- 26% of post-ablation AF recurrence detected beyond 48 hours with Zio 14-day monitoring.
- Up to 1 in 4 post-ablation patients with true AF recurrence could be misclassified by short-duration Holter.
- 60% of arrhythmias in pregnant patients were first detected after 48 hours with Zio.
- Clinically significant arrhythmias were detected in 13.6% of pregnant patients.
- Median analyzable time for Zio in the pregnancy study was 99.2%.
- The post-ablation study included 11,051 patients, and the pregnancy study included 486 patients.
Price Impact
More from IRTC